| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/06/2024 | 22:53 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ABCL | AbCellera Biologics Inc |
| 03/06/2024 | 22:21 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ABCL | AbCellera Biologics Inc |
| 28/05/2024 | 22:05 | Business Wire | AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 07/05/2024 | 22:47 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ABCL | AbCellera Biologics Inc |
| 07/05/2024 | 22:05 | Business Wire | AbCellera Reports Q1 2024 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 01/05/2024 | 15:00 | Business Wire | AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies | NASDAQ:ABCL | AbCellera Biologics Inc |
| 08/04/2024 | 18:05 | Business Wire | AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 03/04/2024 | 22:05 | Business Wire | AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 19/03/2024 | 21:05 | Business Wire | AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/03/2024 | 14:00 | Business Wire | AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions | NASDAQ:ABCL | AbCellera Biologics Inc |
| 05/03/2024 | 22:30 | Business Wire | AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 23/02/2024 | 22:30 | Business Wire | AbCellera Announces Resignation of Board Member | NASDAQ:ABCL | AbCellera Biologics Inc |
| 23/02/2024 | 02:15 | Business Wire | AbCellera to Present at Upcoming Investor Conferences in March | NASDAQ:ABCL | AbCellera Biologics Inc |
| 20/02/2024 | 22:49 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ABCL | AbCellera Biologics Inc |
| 20/02/2024 | 22:05 | Business Wire | AbCellera Reports Full Year 2023 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 23/01/2024 | 22:05 | Business Wire | AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 20/12/2023 | 22:05 | Business Wire | AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 16/11/2023 | 22:05 | Business Wire | AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 03/11/2023 | 17:05 | Business Wire | AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 02/11/2023 | 21:05 | Business Wire | AbCellera Reports Q3 2023 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 01/11/2023 | 21:05 | Business Wire | Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology | NASDAQ:ABCL | AbCellera Biologics Inc |
| 31/10/2023 | 21:05 | Business Wire | AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/10/2023 | 22:05 | Business Wire | AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 27/09/2023 | 15:00 | Business Wire | AbCellera Announces Two T-Cell Engager Presentations at SITC 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 20/09/2023 | 23:02 | Business Wire | AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron | NASDAQ:ABCL | AbCellera Biologics Inc |
| 13/09/2023 | 15:00 | Business Wire | AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology | NASDAQ:ABCL | AbCellera Biologics Inc |
| 03/08/2023 | 22:05 | Business Wire | AbCellera Reports Q2 2023 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 24/07/2023 | 22:05 | Business Wire | AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing | NASDAQ:ABCL | AbCellera Biologics Inc |
| 06/07/2023 | 22:05 | Business Wire | AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 30/05/2023 | 19:15 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ABCL | AbCellera Biologics Inc |